001     153913
005     20240229123053.0
024 7 _ |a 10.1093/glycob/cwaa022
|2 doi
024 7 _ |a pmid:32149357
|2 pmid
024 7 _ |a 0959-6658
|2 ISSN
024 7 _ |a 1460-2423
|2 ISSN
024 7 _ |a altmetric:77290517
|2 altmetric
037 _ _ |a DKFZ-2020-00523
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Jennemann, Richard
|0 P:(DE-He78)3caae9893e3b2704f7bb5a9646ef084d
|b 0
|e First author
|u dkfz
245 _ _ |a Gangliosides Modulate Insulin Secretion by Pancreatic Beta-Cells under Glucose Stress.
260 _ _ |a Oxford
|c 2020
|b Oxford Univ. Press
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1601034626_17569
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a 2020 Aug 20;30(9):722-734#EA:A411#LA:G130#
520 _ _ |a In pancreatic beta cells the entry of glucose and downstream signaling for insulin release is regulated by the glucose transporter 2 (Glut2) in rodents. Dysfunction of the insulin-signaling cascade may lead to diabetes mellitus. Gangliosides, sialic acid-containing glycosphingolipids (GSLs), have been reported to modulate the function of several membrane proteins. Murine islets express predominantly sialylated GSLs, particularly the simple gangliosides GM3 and GD3 having a potential modulatory role in Glut2 activity. Conditional, tamoxifen-inducible gene targeting in pancreatic islets has now shown that mice lacking the glucosylceramide synthase (Ugcg), which represents the rate-limiting enzyme in GSL-biosynthesis, displayed impaired glucose uptake and showed reduced insulin secretion. Consequently, mice with pancreatic GSL deficiency had higher blood glucose levels than respective controls after intraperitoneal glucose application. High fat diet feeding enhanced this effect. GSL-deficient islets did not show apoptosis or ER-stress and displayed a normal ultra-structure. Their insulin content, size and number was similar as in control islets. Isolated beta cells from GM3 synthase null mice unable to synthesize GM3 and GD3 also showed lower glucose uptake than respective control cells, corroborating the results obtained from the cell-specific model. We conclude that in particular the negatively charged gangliosides GM3 and GD3 of beta cells positively influence Glut2 function to adequately respond to high glucose loads.
536 _ _ |a 311 - Signalling pathways, cell and tumor biology (POF3-311)
|0 G:(DE-HGF)POF3-311
|c POF3-311
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
700 1 _ |a Kaden, Sylvia
|0 P:(DE-He78)6093fbefe5b51f07e37146565925d681
|b 1
|u dkfz
700 1 _ |a Volz, Martina
|0 P:(DE-He78)a0a16a2508287abe75725c2a00627ca2
|b 2
|u dkfz
700 1 _ |a Nordström, Viola
|0 P:(DE-He78)9bce4efcbedb17d7b4d0d7832c136faf
|b 3
700 1 _ |a Herzer, Silke
|0 P:(DE-He78)0d110cf9b470ca20bf39544e8c569c27
|b 4
700 1 _ |a Sandhoff, Roger
|0 P:(DE-He78)a928ded2085c8911822370cad0b4a728
|b 5
|u dkfz
700 1 _ |a Gröne, Hermann-Josef
|0 P:(DE-He78)00a2ea610aee4a8fca32908fc3d02e91
|b 6
|e Last author
773 _ _ |a 10.1093/glycob/cwaa022
|g p. cwaa022
|0 PERI:(DE-600)1478140-2
|n 9
|p 722-734
|t Glycobiology
|v 30
|y 2020
|x 1460-2423
909 C O |p VDB
|o oai:inrepo02.dkfz.de:153913
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-He78)3caae9893e3b2704f7bb5a9646ef084d
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-He78)6093fbefe5b51f07e37146565925d681
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 2
|6 P:(DE-He78)a0a16a2508287abe75725c2a00627ca2
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 3
|6 P:(DE-He78)9bce4efcbedb17d7b4d0d7832c136faf
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 4
|6 P:(DE-He78)0d110cf9b470ca20bf39544e8c569c27
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 5
|6 P:(DE-He78)a928ded2085c8911822370cad0b4a728
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 6
|6 P:(DE-He78)00a2ea610aee4a8fca32908fc3d02e91
913 1 _ |a DE-HGF
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-311
|2 G:(DE-HGF)POF3-300
|v Signalling pathways, cell and tumor biology
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
|b Gesundheit
914 1 _ |y 2020
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b GLYCOBIOLOGY : 2017
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
920 2 _ |0 I:(DE-He78)G130-20160331
|k G130
|l Zelluläre und Molekulare Pathologie
|x 0
920 0 _ |0 I:(DE-He78)A411-20160331
|k A411
|l Lipid-Pathobiochemie
|x 0
920 1 _ |0 I:(DE-He78)A411-20160331
|k A411
|l Lipid-Pathobiochemie
|x 0
920 1 _ |0 I:(DE-He78)G130-20160331
|k G130
|l G130 Zelluläre und Molekulare Pathologie
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)A411-20160331
980 _ _ |a I:(DE-He78)G130-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21